What is Alnylam Pharmaceuticals, Inc.'s Market Cap?

Alnylam Pharmaceuticals, Inc.'s Market Cap is $34.8B, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Trailing P/E?

Alnylam Pharmaceuticals, Inc.'s Trailing P/E is 44.9×, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Price / Sales?

Alnylam Pharmaceuticals, Inc.'s Price / Sales is 7.2×, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Revenue (TTM)?

Alnylam Pharmaceuticals, Inc.'s Revenue (TTM) is $4.8B, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Net Income (TTM)?

Alnylam Pharmaceuticals, Inc.'s Net Income (TTM) is $774.7M, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s EBITDA?

Alnylam Pharmaceuticals, Inc.'s EBITDA is $1.1B, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM)?

Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 5.79, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s EBITDA Margin?

Alnylam Pharmaceuticals, Inc.'s EBITDA Margin is 22.0%, based on as-reported figures from SEC (XBRL) filings.

Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements

Alnylam Pharmaceuticals, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001S7FTC8

XNAS · usd

260.09▼ 0.01 (-0.00%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value—

Trailing P/E

Price / Sales

EV / Revenue—

EV / EBITDA—

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt—

Trading Information

Previous Close260.10

Day's Range254.01 – 272.08

52-Week Range197.81 – 495.55

Volume2.0M

Avg Volume2.2M

Share Statistics

Shares Outstanding

Employees2,500

ExchangeXNAS

Listed2004-05-28

Share count as of July 24, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Alnylam Pharmaceuticals, Inc. (ALNY)

What is Alnylam Pharmaceuticals, Inc.'s Market Cap?: Alnylam Pharmaceuticals, Inc.'s Market Cap is $34.8B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Trailing P/E?: Alnylam Pharmaceuticals, Inc.'s Trailing P/E is 44.9×, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Price / Sales?: Alnylam Pharmaceuticals, Inc.'s Price / Sales is 7.2×, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Revenue (TTM)?: Alnylam Pharmaceuticals, Inc.'s Revenue (TTM) is $4.8B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Net Income (TTM)?: Alnylam Pharmaceuticals, Inc.'s Net Income (TTM) is $774.7M, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s EBITDA?: Alnylam Pharmaceuticals, Inc.'s EBITDA is $1.1B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM)?: Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 5.79, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s EBITDA Margin?: Alnylam Pharmaceuticals, Inc.'s EBITDA Margin is 22.0%, based on as-reported figures from SEC (XBRL) filings.